TRP_1170x120_3-8-19

Carol Lynch

Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi U.S. patent case

Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi U.S. patent case

HOLZKIRCHEN, Germany  – Sandoz, a Novartis division and a global leader in biosimilars, today announced that the United States District Court of New Jersey ruled against Sandoz in patent litigation concerning the Sandoz biosimilar, Erelzi (etanercept-szzs) for reference medicine Enbrel (etanercept). The company will appeal the ruling to the US Court of Appeals for the

Sandoz donation protecting against severe allergic reactions

Sandoz donation protecting against severe allergic reactions

STAMFORD, Conn. – Americares is delivering epinephrine to free and charitable clinics across the United States to protect children and adults from serious allergic reactions as they spend more time outdoors this summer. The Sandoz division of Novartis recently donated more than 4,000 packs (over 8,000 individual injections) of its Symjepi (epinephrine) 0.3 mg Injectable medication